Tykerb is approved now as one of the most progressive drug in combination with letrozole for the treatment of hormone-receptor-positive metastatic breast cancer with overexpression HER2 after the menopause period.

Oleptro extended release tablets are taken orally once a day at any time (morning or evening). A double-blind, randomized clinical investigation carried for a period of 8 weeks has proved the effectiveness and safety profile of the Oleptro.